CYTOCHROME-P450IID SUBFAMILY IN NONHUMAN-PRIMATES - CATALYTICAL AND IMMUNOLOGICAL CHARACTERIZATION

被引:21
作者
JACQZAIGRAIN, E
GUEGUEN, M
ZANGER, UM
ROBIEUX, I
ALVAREZ, F
机构
[1] HOP BICETRE,INSERM,U56,F-94275 LE KREMLIN BICETR,FRANCE
[2] UNIV BASEL,BIOCTR,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND
关键词
D O I
10.1016/0006-2952(91)90166-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interindividual variations of debrisoquine metabolism was recently identified in non-human primates tested in vivo. The catalytical and immunological characterization of cytochrome P450IID subfamily was undertaken in hepatic microsomes from extensive metabolizer primates. The NADPH/O2 mediated metabolism of debrisoquine, dextromethorphan and bufuralol was similar to the kinetics reported in humans. The CuOOH mediated metabolism of bufuralol suggested that at least two enzymes are responsible for bufuralol 1'-hydroxylation. Eleven compounds were tested for their capacity to modify P450IID function in vitro. Eight competitive inhibitors of P450IID6 in man were all and exclusively competitive inhibitors of P450IID subfamily in non-human primates. Quinidine, which is the strongest competitive inhibitor in man, exhibited the higher inhibitory potency in monkey (K(i) = 0.75-mu-M). Anti-LKM antibody against P450IID subfamily cross-reacted with two proteins of 49 and 47 kDa, and sera containing anti-LKM antibody against these two proteins inhibited dextrorphan formation in vitro. These data provide evidence for catalytical and immunological similarities between human and monkey microsomes and indicate that the primate system could be a model for enzymatic studies of P450IID.
引用
收藏
页码:1657 / 1663
页数:7
相关论文
共 37 条
[1]   ANTI LIVER-KIDNEY MICROSOME ANTIBODY RECOGNIZES A 50,000 MOLECULAR-WEIGHT PROTEIN OF THE ENDOPLASMIC-RETICULUM [J].
ALVAREZ, F ;
BERNARD, O ;
HOMBERG, JC ;
KREIBICH, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1231-1236
[2]   RELEVANCE OF GENETIC-POLYMORPHISM IN DRUG-METABOLISM IN THE DEVELOPMENT OF NEW DRUGS [J].
BALANT, LP ;
GUNDERTREMY, U ;
BOOBIS, AR ;
VONBAHR, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :551-554
[3]   BUFURALOL 1'-HYDROXYLASE ACTIVITY OF THE RAT - STRAIN DIFFERENCES AND THE EFFECTS OF INHIBITORS [J].
BOOBIS, AR ;
SEDDON, CE ;
DAVIES, DS .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (17) :2961-2965
[4]  
BOOBIS AR, 1983, MOL PHARMACOL, V23, P474
[5]   GENETIC-POLYMORPHISM IN DRUG OXIDATION - INVITRO STUDIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE AND BUFURALOL 1'-HYDROXYLASE ACTIVITIES [J].
BOOBIS, AR ;
MURRAY, S ;
HAMPDEN, CE ;
DAVIES, DS .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (01) :65-71
[6]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[7]  
CODONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
[8]  
COSTESEC AM, 1974, J CELL BIOL, V61, P201
[9]   DEXTROMETHORPHAN O-DEMETHYLATION IN LIVER-MICROSOMES AS A PROTOTYPE REACTION TO MONITOR CYTOCHROME-P-450 DB1 ACTIVITY [J].
DAYER, P ;
LEEMANN, T ;
STRIBERNI, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (01) :34-40
[10]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187